 randomized trial cisplatin vinblastine versus vinblastine cisplatin treatment advanced germ cell tumors testis Southwest Oncology Group study Southwest Oncology Group SWOG trial cisplatin vinblastine bleomycin PVB versus vinblastine cisplatin VPV treatment advanced germ cell tumors testis study objective effect replacement bleomycin complete response CR survival drug toxicity sixty-nine patients patients assessable response disseminated germ cell neoplasms testicular origin Forty-six minimal metastatic disease maximal disease Seventy-seven PVB VPV chemotherapy significant difference pretreatment characteristics arms regard burden histologic type overall performance status Patients courses induction chemotherapy PVB cisplatin day vinblastine day week VPV vinblastine day cisplatin day days Chemotherapy weeks Cytoreductive surgery postinduction chemotherapy CR difference percentage patients disease-free status PVB VPV mean leukocyte nadir similar treatments mean platelet nadir VPV arm bleomycin-related toxicities pulmonary mucositis skin VPV arm bleomycin first-line therapy advanced germ cell tumors efficacy advantage unnecessary drug toxicity